Sanofi (NASDAQ:SNY) Shares Acquired by GeoWealth Management LLC

GeoWealth Management LLC raised its position in shares of Sanofi (NASDAQ:SNY) by 56.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 15,256 shares of the company’s stock after acquiring an additional 5,500 shares during the period. GeoWealth Management LLC’s holdings in Sanofi were worth $736,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of SNY. Arkadios Wealth Advisors raised its holdings in Sanofi by 19.0% in the fourth quarter. Arkadios Wealth Advisors now owns 4,709 shares of the company’s stock valued at $227,000 after buying an additional 751 shares during the period. Geode Capital Management LLC raised its stake in shares of Sanofi by 7.1% in the 3rd quarter. Geode Capital Management LLC now owns 254,738 shares of the company’s stock valued at $14,681,000 after acquiring an additional 16,780 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Sanofi by 20.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company’s stock valued at $133,172,000 after acquiring an additional 399,301 shares in the last quarter. Kentucky Trust Co purchased a new stake in Sanofi during the 4th quarter worth $436,000. Finally, World Investment Advisors LLC increased its holdings in Sanofi by 1,020.5% in the 3rd quarter. World Investment Advisors LLC now owns 48,430 shares of the company’s stock valued at $2,791,000 after purchasing an additional 44,108 shares in the last quarter. 14.04% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Stock Performance

Sanofi stock opened at $50.90 on Monday. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. The stock has a 50 day moving average of $54.73 and a 200-day moving average of $52.14. The stock has a market cap of $128.59 billion, a P/E ratio of 20.44, a price-to-earnings-growth ratio of 1.01 and a beta of 0.57. Sanofi has a 52 week low of $45.80 and a 52 week high of $60.12.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. On average, analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.

Sanofi Increases Dividend

The company also recently disclosed an annual dividend, which will be paid on Thursday, June 12th. Shareholders of record on Friday, May 9th will be paid a dividend of $2.0369 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a yield of 3.1%. This is a boost from Sanofi’s previous annual dividend of $1.48. Sanofi’s dividend payout ratio is presently 64.26%.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on SNY shares. BNP Paribas assumed coverage on Sanofi in a research report on Tuesday, April 15th. They issued an “outperform” rating and a $65.00 target price for the company. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Finally, The Goldman Sachs Group started coverage on shares of Sanofi in a research note on Friday, March 21st. They issued a “neutral” rating and a $65.00 target price for the company. Three equities research analysts have rated the stock with a hold rating, two have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $63.33.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.